🔬Biotech Startup Raises $311M for AI-Driven Drug Discovery
AI drug discovery just got $311M to find new meds
TL;DR
A biotech startup raised $311M to accelerate drug discovery using AI, doubling its valuation to $2B. The funds will support clinical trials for several drugs targeting severe skin conditions and weight loss maintenance.
A biotech startup has raised a whopping $311 million in Series E funding, doubling its valuation to $2 billion. Led by Catalio Capital Management with participation from Iconiq and others, the startup aims to use AI to discover new drugs in the natural world. This funding will accelerate the development of several drugs currently in human clinical trials, targeting severe skin conditions and weight loss maintenance after stopping GLP-1s. For developers and researchers in the field, this means more resources and faster progress in AI-driven drug discovery, potentially speeding up the time to market for new treatments. The startup, founded in 2019 by an early employee of Recursion Pharmaceuticals, is among the first to advance AI-discovered candidates into human clinical trials, marking a significant milestone in the industry.
Key Points
Startup raised $311 million in Series E funding, led by Catalio Capital Management.
Valuation doubled to $2 billion in the past 12 months.
Funding will support clinical trials for drugs targeting severe skin conditions and weight loss maintenance.
Startup uses AI to discover new drugs in the natural world, speeding up the drug discovery process.
Company is among the first to advance AI-discovered candidates into human clinical trials.
Why It Matters
If you're working on AI-driven drug discovery, this $311M funding round is a huge boost. The startup's valuation doubling to $2 billion shows the potential for AI in finding new medicines faster. This could mean quicker access to treatments for severe skin conditions and weight loss maintenance, benefiting patients and researchers alike. The startup's progress in clinical trials is a significant milestone for the industry.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.